Viread Prescribing Information from the FDA Web site [PDF]. A more current version may be available on the manufacturer's Web site.
PMID/16496322 Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, Rozenbaum W, Le Teuff G, Trylesinski A, Piketty C; TECOVIR Study Group. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Hepatology. 2006 Mar;43(3):548-55.
PMID/17503745 Gerard L, Chazallon C, Taburet AM, Girard PM, Aboulker JP, Piketty C. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir. Antivir Ther. 2007;12(1):31-9.
PMID/17545703 Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, Lazzarin A, Schewe K, Lange J, Wyatt C, Curtis S, Chen SS, Smith S, Bischofberger N, Rooney JF. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007 Jun 19;21(10):1273-81.
PMID/17525796 Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K, Grant R, Clarke EE, Doh AS, Ridzon R, Jaffe HS, Cates W. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007 May 25;2(5):e27.
PMID/16863446 Pham PA, Gallant JE. Tenofovir disoproxil fumarate for the treatment of HIV infection. Expert Opin Drug Metab Toxicol. 2006 Jun;2(3):459-69.
PMID/12965939 Squires K, Pozniak AL, Pierone G Jr, Steinhart CR, Berger D, Bellos NC, Becker SL, Wulfsohn M, Miller MD, Toole JJ, Coakley DF, Cheng A; Study 907 Team. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med. 2003 Sep 2; 139(5 Pt 1):313-20. Summary for patients in: Ann Intern Med. 2003 Sep 2; 139(5 Pt 1):I22.
|
[1] Gilead Sciences - Viread Prescribing Information, May 2007, p. 1. Available at: http://www.gileadhiv.com/pdf/VireadFPI.pdf. Accessed 10/16/07. [2] FDA - Drugs Used in the Treatment of HIV Infection. Available at: http://www.fda.gov/oashi/aids/virals.html. Accessed 10/16/07. [3] FDA - Viread Prescribing Information, 05/21/07, p. 2. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [4] ClinicalTrials.gov - A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV. Available at: http://www.clinicaltrials.gov/ct/show/NCT00033163. Accessed 10/16/07. [5] ClinicalTrials.gov - Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy. Available at: http://www.clinicaltrials.gov/ct/show/NCT00109603. Accessed 10/16/07. [6] ClinicalTrials.gov - Safety and Effectiveness Study of a Candidate Vaginal Microbicide for Prevention of HIV. Available at: http://clinicaltrials.gov/ct/show/NCT00441298?order=2. Accessed 10/16/07. [7] Antimicrob Agents Chemother - 2006 Jul;50(7):2471-7 [8] Antivir Ther - 2004 Jun;9(3):353-63 [9] FDA - Supplemental New Drug Approval Letter. Available at: http://www.fda.gov/cder/foi/appletter/2008/021356s025ltr.pdf. Accessed: 08/15/08. [10] MEDLINEPlus Drug Information - Viread Approved for Hepatits B [article]. Available at: http://www.nlm.nih.gov/medlineplus/news/fullstory_68069.html . Accessed: 08/15/08. [11] Hepatology - 2006 Aug;44(2):318-25 [12] ClinicalTrials.gov - A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV. Available at: http://www.clinicaltrials.gov/ct/show/NCT00033163. Accessed 10/16/07. [13] FDA - Viread Prescribing Information, 05/21/07, p. 24. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [14] FDA - Viread Prescribing Information, 05/21/07, p. 25. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [15] FDA - Viread Prescribing Information, 05/21/07, p. 24-5. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [16] FDA - Viread Prescribing Information, 05/21/07, p. 25. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [17] FDA - Viread Prescribing Information, 05/21/07, p. 2. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [18] FDA - Viread Prescribing Information, 05/21/07, p. 4. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [19] FDA - Viread Prescribing Information, 05/21/07, p. 5. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [20] FDA - Viread Prescribing Information, 05/21/07, p. 16. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [21] FDA - Viread Prescribing Information, 05/21/07, p. 5. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [22] FDA - Viread Prescribing Information, 05/21/07, p. 5. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [23] FDA - Viread Prescribing Information, 05/21/07, pp. 5-6. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [24] FDA - Viread Prescribing Information, 05/21/07, p. 3. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [25] FDA - Viread Prescribing Information, 05/21/07, p. 3. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [26] AHFS Drug Information - 2007; p. 736 [27] Wolters Kluwer Health, Inc. - Abacavir Sulfate, Facts and Comparisons 4.0. Available at: http://online.factsandcomparisons.com. Accessed 10/16/07. [28] FDA - Viread Prescribing Information, 05/21/07, p. 14. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [29] FDA - Viread Prescribing Information, 05/21/07, p. 13. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [30] FDA - Viread Prescribing Information, 05/21/07, pp. 15-6. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [31] FDA - Viread Prescribing Information, 05/21/07, p. 15. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [32] FDA - Viread Prescribing Information, 05/21/07, p. 24. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [33] FDA - Viread Prescribing Information, 05/21/07, p. 14. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [34] FDA - Viread Prescribing Information, 05/21/07, p. 14. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [35] FDA - Viread Prescribing Information, 05/21/07, p. 14. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [36] FDA - Viread Prescribing Information, 05/21/07, p. 7. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [37] FDA - Viread Prescribing Information, 05/21/07, p. 8. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [38] FDA - Viread Prescribing Information, 05/21/07, p. 8. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [39] FDA - Viread Prescribing Information, 05/21/07, p. 8. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [40] FDA - Viread Prescribing Information, 05/21/07, p. 14. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [41] FDA - Viread Prescribing Information, 05/21/07, p. 6. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [42] FDA - Important New Clinical Data, Potential Early Virologic Failure Associated With the Combination Antiretroviral Regimen of Tenofovir Disoproxil Fumarate, Didanosine, and Either Efavirenz or Nevirapine in HIV Treatment-Naive Patients with High Baseline Viral Loads. [Dear Healthcare Professional Letter]. New York: Bristol-Myers Squibb; Available at: http://www.fda.gov/oashi/aids/listserv/bms.pdf. Accessed 10/16/07. [43] FDA - Viread Prescribing Information, 05/21/07, p. 13. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [44] FDA - Viread Prescribing Information, 05/21/07, p. 13. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [45] ChemIDplus - Available at: http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp. Accessed 10/16/07. [46] ChemIDplus - Available at: http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp. Accessed 10/16/07. [47] ChemIDplus - Available at: http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp. Accessed 10/16/07. [48] Calculation. - [49] FDA - Viread Prescribing Information, 05/21/07, p. 1. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [50] FDA - Viread Prescribing Information, 05/21/07, p. 1. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [51] FDA - Viread Prescribing Information, 05/21/07, p. 1. Available at: http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011lbl.pdf. Accessed 10/16/07. [52] ChemIDplus - Available at: http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp. Accessed 10/16/07. [53] ChemIDplus - Available at: http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp. Accessed 10/16/07.
|